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Fine Tuning of Antibiotic Activity by a Tailoring Hydroxylase in a 
Trans-AT Polyketide Synthase Pathway 
Hadi H. Mohammad[a,d], Jack A Connolly[a], Zhongshu Song[b], Joanne Hothersall[a], Paul R Race[c], 
Christine L Willis[b], Thomas J Simpson[b], Peter J Winn[a] and Christopher M Thomas*[a] 
 
Abstract: Addition or removal of hydroxyl groups modulates the 
activity of many pharmacologically active biomolecules. It can be 
integral to the basic biosynthetic factory or result from associated 
tailoring steps. For the anti-MRSA antibiotic mupirocin, removal of a 
C8-hydroxy group late in the biosynthetic pathway gives the active 
pseudomonic acid A.  An extra hydroxylation, at C4, occurs in the 
related but more potent antibiotic thiomarinol A. We report here in 
vivo and in vitro studies that show putative non-heme-iron(II)/α-
ketoglutarate-dependent dioxygenase TmuB, from the thiomarinol 
cluster, 4-hydroxylates various pseudomonic acids while C8-OH, 
and other substituents around the pyran ring, block enzyme action 
but not substrate binding. Molecular modelling suggested a basis for 
selectivity but mutational studies showed limited ability to rationally 
modify TmuB substrate specificity. 4-hydroxylation had opposite 
effects on the potency of mupirocin and thiomarinol. Thus TmuB can 
be added to the toolbox of polyketide tailoring technologies for in 
vivo generation of new antibiotics in the future. 
Polyketide synthases (PKSs) build carbon backbones of 
complex molecules from simple building blocks, such as acetate 
and malonate, using enzymes similar to those found in fatty acid 
biosynthesis.[1] Further “tailoring” of these backbones (e.g. via 
hydroxylation) to produce the final product can be critical and 
understanding the specificity of such enzymes is essential for 
assembly of new pathways to novel compounds. For example, 
cyclosporin loses its immunosuppressive activity after regio-
specific hydroxylation at the 4th N-methyl leucine but retains its 
side effects on hair growth.[2] 
Hydroxyl groups in polyketides generally occur either by 
ketoreduction of β-keto thiol esters, or on α-carbons of thiol 
esters by a tailoring step. β-hydroxy groups can be predicted 
from the pks gene sequences while α-hydroxylation is less 
predictable. PKS pathways use a number of enzyme families for 
hydroxylation of α-carbons: cytochrome P450s,[3] FAD-binding 
monooxygenases[4] and non-hemeFe(II)/α-ketoglutarate 
dependent dioxygenases.[5] 
To provide new tools for engineering biosynthetic 
pathways we have investigated tailoring reactions in pathways of 
two closely related antibiotics from the trans-AT family of 
modular polyketides,[6] namely the thiomarinols and  mupirocin. 
Thiomarinols (e.g. 1 and 2) are produced by marine bacteria of 
the genus Pseudoalteromonas and are closely related to the 
commercially important mupirocin[7] (a mixture of pseudomonic 
acids including A-C 3-5, Fig. 1) produced by Pseudomonas 
fluorescens which is used topically against Methicillin Resistant 
Staphylococcus aureus (MRSA).[8] The structures of the major 
metabolites, thiomarinol A 1 and pseudomonic acid A (PA-A, 3), 
differ by the presence of a 10, 11-alkene in 1 but an epoxide in 3, 
an 8-hydroxyoctanoic acid rather than 9-hydroxynonanoic acid 
side-chain and an additional pyrrothine moiety. A further 
important difference for the current study, is that the more 
bioactive thiomarinol A 1 possesses a 4-hydroxyl group[7].  Most 
genes in the mupirocin gene cluster have been allocated a role[9] 
and sequence comparisons of the mup and tml gene clusters 
confirms the similarities but important differences in their 
biosynthetic pathways.[10] 
 
 
Figure 1. Structures of key compounds in this study. (A) Selected thiomarinols 
and pseudomonic acids; (B) Synthetic conversion of PA-A 3; (C) Further 4-
hydroxylated metabolites and mupirocin F; (D) Mupirocins not 4-hydroxylated 
by TmuB.  
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Understanding these differences might allow modification of 
mupirocin and other molecules to give new antibiotic leads. 
Feeding experiments with the PKS mutant of the thiomarinol 
producer Pseudoalteromonas spp SANK73390 showed that PA-
A 1, could be 4-hydroxylated and addition of the pyrrothine 
occurred giving 6, 7 and 8 (Figure 1B).  In contrast, PA-B 2, with 
the 8-OH, gained the pyrrothine but no 4-hydroxylation 
occurred.[11]  Here we identify the 4-hydroxylase as TmuB and 
report its characterisation. 
 
Results and Discussion 
TmuB can 4-hydroxylate metabolites in P. fluorescens  
Comparison of the mupirocin and thiomarinol gene clusters 
identified genes that lack paralogues in the mupirocin cluster 
and might encode the 4-hydroxylase. BLAST searches[12] 
identified TmuB as related to phytanoyl-CoA dioxygenase, an 
enzyme of the non-heme-iron(II)/αKG-dependent dioxygenase 
superfamily. We inserted the tmuB coding region into broad host 
range vector pJH10 under control of the tac promoter (pJH10-
tmuB) and transferred it to WT P. fluorescens NCIMB 10586. 
HPLC analysis of culture supernatant after tmuB expression 
showed a new peak more polar than PA-A (Fig. 2). The new 
metabolite was isolated and confirmed by NMR spectroscopy to 
be 4-hydroxy PAA 6.   
 
Figure 2. HPLC analysis of culture supernatant from P. fluorescens strains 
showing that TmuB modifies PA-A 1 and PA-C 3 (produced by mmpEΔOR) 
but not PA-B 2 (produced by ΔmupU). Mupirocin F 4 is also 4-hydroxylated. 
Note also that tmuB expression increased overall yield of pseudomonic acid 
derivatives, so a new peak can appear even though the peak of the non-4-
hydroxylated form is of a similar size to that observed without tmuB. 
 
We expressed tmuB in P. fluorescens NCIMB10586 mutants 
that accumulate different intermediates to explore substrate 
specificity. As predicted from feeding PA-B 4 to the thiomarinol 
producer[11], tmuB expressed in mutants ΔmacpE, ΔmupO, 
ΔmupU and ΔmupV that produce PA-B rather than PA-A[15] did 
not change PA-B metabolite profile (Fig. 2), strengthening the 
conclusion that TmuB has specificity for PA-A 3 over PA-B 4.  
Expression in NCIMB10586 ΔmupC producing mupirocin C 13, 
and ΔmupT or ΔmupW producing mupirocin W 14 (structures 
shown in Fig. 1) gave no significant differences in metabolite 
profiles (data not shown). However, the mmpEΔOR strain 
producing PA-C 5, gave a new metabolite (Fig. 2) confirmed as 
4-hydroxy PA-C 9 following full characterisation by MS and NMR  
(Table 1S). Likewise ΔmupF, producing mupirocin F 10 gave the 
novel metabolite (Fig. 2) confirmed to be 4-hydroxy mupirocin F 
by LC-ESI-MS (MW=514) and NMR (Table 1S).  Interestingly 
the mupirocin F peak at 22.3 min increased two-fold (Fig. 2), an 
example of increased overall production observed when tmuB is 
expressed. Thus the tetrahydropyran ring and its state of 
oxidation are critical for substrate modification by TmuB and it is 
not only an 8-OH group that can block the action of TmuB.  
 
PA-B 4 is a competitive inhibitor of purified TmuB 
WT tmuB was inserted into pET28a and expressed in E. coli 
BL21(DE3) with an N-terminal His-tag. As a control, tmuB from 
inactive mutant I109N, described below, was expressed in 
parallel. Purified WT and I109N TmuB protein were tested on 
purified PA-A 3. Co-substrate (α-ketoglutaric acid) and co-factor 
(FeSO4) were essential and WT TmuB generated a new peak at 
18.2 min (Fig. 3A) confirmed to be 4-hydroxy PA-A 6 but TmuB 
I109N did not. Reactions at 23 oC, 25 oC, 30 oC and 37 oC for 
180 min, showed maximum activity at 23 oC, the optimum 
growth temperature for the thiomarinol producer.  
TmuB activity on PA-B was only observed after >6h 
incubation, generating a new metabolite (Figure 3A), confirmed 
as 4-hydroxy PA-B 12 (Fig. 1) by LCMS and NMR. Initial rates 
were determined at substrate concentrations from 3.75 to 240 
µM to determine Vmax and Km (Fig. 3B, C, D).  The catalytic 
efficiency (kcat/Km) for PA-A is three orders of magnitude higher 
than for PA-B, the major difference being turnover number rather 
than substrate binding (Fig. 3D). 
Since the Km for PA-B 4 is only 3-fold higher than for PA-A, 
while turnover number decreases 1000-fold, it may be a 
competitive inhibitor of TmuB.  Reactions on PA-A 3 carried out 
with 30, 60 and 120 µM PA-B showed an increased Km for PA-A 
while kcat remained unchanged (Figure 1S). The apparent 
absence of hydroxylation of PA-B and other derivatives by TmuB 
in vivo may be due to this slow reaction rate: the product may be 
released from the cell before hydroxylation occurs or remain 
below the detection limit.  
 
Mutational analysis of the TmuB substrate binding pocket 
In the absence of TmuB crystallographic data, structural 
predictions were made from the coordinates of EasH[13] (PDB 
4NAO, 25% identity), plus AsqJ (PDB 5DAW, 21% identity)[14]  
and FtmOx1 (PDB 4Y5T, 23% identity)[15] because 4NAO lacks 
coordinates for the α-helix2/β3 loop which is resolved as a flap 
covering the active site entrance in the others (Fig. 2S). The 
TmuB homology model contains a double stranded β-helix 
(DSBH), or Jelly-roll fold, characteristic of the nonheme-Fe(II)/α-
ketoglutarate-dependent dioxygenase super-family (Fig. 3S) [16].  
PA-A 3 was docked with the best scoring models based on the 
criteria listed in Methods, with and without the α-helix2/β3 loop 
folded properly, to find dominant conformations/orientations 
consistent with the known biochemistry and identify residues 
interacting with the substrate. Without the α-helix2/β3 loop, the 
results show monic acid fitting the active site pocket and 9HN in 
the external groove (Fig. 4A). When the α-helix2/β3 loop is 
included it is located above the active site and interacts with the 
fatty acid chain (Fig. 4S). The tetrahydropyran ring was similarly 
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located in all models. Evolutionary Trace Analysis (ETA) 
identified about half the residues lining the pocket as likely to be 
functionally important (Fig.5S) and this is supported by 
mutagenesis experiments in other proteins[17]. For PA-A the 
target C-4 is 4.4 Å from the Fe cofactor which is close to the 
norm (4.5 Å) for these enzymes[18]. The pyran ring sits near the 
pocket entrance which consists of residues R69, K105, I109 and 
M208 and interacts with R69, K105 and I109 plus L141 and 
A206 (Fig. 4B and C). 
To explore specificity, PA-B 4 was docked with the TmuB 
model using the same parameters as for PA-A 3. Similar 
orientations were obtained and although binding energy and 
inhibitory constants for both PA-A 3 and PA-B 4 were similar, the 
 Figure 3. In vitro activity of TmuB and kinetics using different substrates. A: 
Activity of purified TmuB on PA-A 3 gives complete 4-hydroxylation of PA-A 3 
to 6 but only 43% 4-hydroxylation of PA-B 4 after overnight incubation; B: 
Michaelis-Menten analysis of TmuB hydroxylating PA-3 and TMC 2; C: 
Analysis of TmuB hydroxylating PA-B; and D. The enzyme kinetic parameters 
of TmuB for each substrate. 
Figure 4. A. Homology model of TmuB showing PA-A 3 docked in the active 
site. 9HN fits into the external groove while monic acid inserts into the pocket, 
B. PA-A (Pink stick) and proximal residues in the active site. The target site C-
4 is 4.38 Å from the Fe II (Orange sphere), C. The active site residues 
surrounding the pyran ring and were selected for mutagenesis.  D. The effect 
of mutations on TmuB activity against PA-A.   
C4 to active site Fe2+ distance was 6.3 Å compared to 4.4 Å for 
PA-A 3. Thus the C-8 OH must alter the active site fit and 
detailed analysis showed that R69, D104, K105, I109, Q126, 
L141 and M208 may be involved. All these residues were 
mutated to smaller, hydrophilic amino acids to accommodate the 
extra groups. Substitutions least likely to cause TmuB 
inactivation were identified by alignments with other superfamily 
members and in silico mutation. Single and double tmuB point 
mutants were created in pJH10-tmuB and tested for PA-B 
hydroxylation in P. fluorescens: HPLC analysis showed that 
none gave observable hydroxylation but some reduced activity 
on PA-A (Fig. 4D). That 4-OH PA-B 12 might be lethal is unlikely 
given the MIC data presented below (Fig. 5) and the possibility 
that it is trapped in the cell seems unlikely since hydroxylated 
metabolites were easily isolated from culture supernatants. Thus 
it may not be possible to manipulate TmuB to allow in vivo 
hydroxylation of PA-B. 
 
Effect of hydroxylation on antibacterial activity 
Plate bioassay (plus 0.5 mM IPTG) showed that 
antibacterial activity of 4-hydroxylated mupirocin produced in 
vivo by NCIMB10586 (pJH10-tmuB) (mainly 4-hydroxy PA-A 6) 
was reduced against B. subtilis 1064 (Fig. 5A) and MIC tests 
confirmed this (Fig. 5C). Lowered activity of 4-OH PA-B makes it 
unlikely that failure to convert in vivo is due to lethality. To 
explore explanations for the reduction, PA-A was docked to the 
crystal structure of the isoleucyl-tRNA synthetase (IleRS) in 
silico, yielding a conformation similar to the crystal complex of 
IleRS-PA-A (1FFY PDB)[19].  The hydroxyl group in 4-OH PA-A 6 
disrupted this conformation apparently because the 4-OH 
causes steric repulsion by H64 and D557 (Fig. 6S). To test the 
effect of thiomarinol lacking the 4-hydroxy group, a sample of 
thiomarinol C 2 (Fig. 1) was prepared after the tmuB I109N 
A B 
C D 
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mutation was recombined into the thiomarinol producer.  
Bioassay and MIC tests with B. subtilis, E. coli and S. aureus 
showed that thiomarinol C (TMC) 2 was less potent than 
thiomarinol A 1 (Fig. 5). The different consequences of 4-
hydroxylation on potency of PAs versus TMs may indicate that 
the length of hydroxy-acid moiety (9NA v 8HO) alters how these 
antibiotics bind their targets and emphasises the need for 
structures of more IleRS-antibiotic complexes.  
In vitro tests with purified TmuB showed thiomarinol C 2 is 
a good substrate for TmuB giving thiomarinol A 1 with similar 
catalytic activity to PA-A 3 (Km= 29.5 µM and kcat = 2212 s-1) (Fig. 
3B). 
 
Figure 5. Antibacterial activity of the new derivatives. (A) Plate bioassays 
against B. subtilis from P. fluorescens strains expressing TmuB in-trans: P. 
fluorescens WT (producing 4-OH PA-A 6), P. fluorescens mmpEΔO 
(producing 4-OH PA-C 9) and P. fluorescens ΔmupF (producing 4-OH 
mupirocin F 11). (B) Plate bioassays on Thiomarinol A and C (1 and 2) 
extracted from WT and PM I109N SANK respectively. The discs were 
saturated with 100 µg of purified thiomarinol A and C and tested against B. 
subtilis 1064, E. coli DH5α and S. aureus MRSA NCTC 12493. (C) Minimal 
inhibitory concentrations (MIC).  
 
Conclusions 
We have shown that TmuB 4-hydroxylates thiomarinol and its 
analogues including PA-A 3, PA-C 5 and mupirocin F 10 in P. 
fluorescens.  However, its activity is severely inhibited, not just 
by the 8-OH of PA-B 4, but also by the further structural changes 
to the tetrahydropyran core (as in mupirocins C and W, 13 and 
14). It therefore seems likely that 4-hydroxylation occurs late in 
biosynthesis especially since an ACP-tethered substrate is not 
required, as TMC 2 and PA-C 5 are good substrates. We also 
conclude that the 9HN/8HO moiety must remain outside the 
active site pocket since its internal dimensions of 6.8Å by 4.4Å 
would be too small to accommodate the C1-3 of monic acid, 
8HO and pyrrothine in the pocket. 4-hydroxylation could 
therefore be one of the final steps in biosynthesis and tmuB 
could have been acquired relatively recently in thiomarinol 
cluster evolution, consistent with it being one of the genes (tmlY, 
tmuA and tmuB) not present in the mup cluster[10]. The fact that 
4-hydroxylation increases thiomarinol potency could explain this 
acquisition but since tmuB expression also increased product 
levels in culture supernatants, enhancing passage across the 
membrane could be another explanation. 
The detectable but low activity of TmuB on PA-B 5 
suggested that TmuB might be modified to hydroxylate a 
broader range of substrates. Active site mutagenesis of 
enzymes of the nonheme-Fe(II)/αKG-dependent dioxygenase 
superfamily has changed specificity and diverted catalytic 
function as reported recently with fumitremorgin B 
endoperoxidase from Aspergillus fumigatus[15]. However, 
structure-guided site directed mutagenesis failed to improve the 
activity of our enzyme. This may be due to TmuB having flexible 
finger-like loops like those found in enzymes such as phytanoyl-
CoA dioxygenase[20] and prolyl hydroxylase[21], which undergo 
conformational changes on substrate binding, making in silico 
substrate docking difficult. Therefore, determining accurate 
TmuB crystal structures with and without different substrates will 
be an important goal to increase its uses in polyketide tailoring 
technologies and facilitate the in vivo generation of new 
antibiotics in the future. 
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